# US 2026/0090988 A1 · Pharmaceutical compositions for the treatment of ophthalmic conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0090988 A1
- Document ID: US20260090988A1
- Status: Published application
- Kind: A1
- Application number: 19/283,647
- Filed: 2025-07-29
- Published: 2026-04-02
- Earliest claimed: 2017-08-27
- Assignees: Rhodes Technologies
- Applicants: Rhodes Technologies
- Inventors: Ping CHANG; Zhenze HU; Yuanyuan TAO
- Web page: https://patentgrep.com/patent/US20260090988A1

## CPC

- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/07: Retinol compounds, e.g. vitamin A (retinoic acids A61K31/203)
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 27/06: Antiglaucoma agents or miotics
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61P 27/04: Artificial tears; Irrigation solutions
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides emulsion compositions comprising at least one cannabinoid compound, and methods for making the same. The emulsion compositions are stable, well tolerated and are capable of delivering therapeutically effective amounts of cannabinoids to target sites, including sites on the surface of and/or within an eye. Also provided are methods of using the compositions to provide ocular neuroprotection and/or to treat ophthalmic conditions such as glaucoma.

## Claims

### Claim 1

An emulsion composition comprising:
a pharmaceutically effective amount of tetrahydrocannabinol (THC), or a derivative thereof;
an oil;
a surfactant; and
water,
wherein the emulsion comprises an oil phase component comprising a plurality of oil droplets, dispersed with an aqueous phase component, wherein the THC is (−)-trans-Δ9-tetrahydrocannabinol and the pharmaceutically effective amount of THC is an amount effective for treating or preventing an ophthalmic condition in a patient to whom the emulsion composition is administered.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The emulsion composition of claim 1, wherein the emulsion composition remains stable after being stored at a condition selected from the group consisting of: at least two years at about −18° C.; at least three months at about 4° C.; and at least one month at about 23° C., such that there is an absence of visible phase separation between the oil phase component and the aqueous phase component after such storage condition.

### Claim 4 (depends on 1)

The emulsion composition of claim 1, wherein the composition is an eye drop solution.

### Claim 5 (depends on 1)

The emulsion composition of claim 1, wherein the ratio (w/w) of oil to water in the composition is in the range of about 1:10 to about 1:1000.

### Claim 6 (depends on 1)

The emulsion composition of claim 1, wherein the ratio (w/w) of oil to water in the composition is in the range of about 1:20 to about 1:100.

### Claim 7 (depends on 1)

The emulsion composition of claim 1, wherein the emulsion is substantially free of antimicrobial preservative agents.

### Claim at position 8

-13. (canceled)

### Claim 14 (depends on 1)

The emulsion composition of claim 1, wherein the pharmaceutically effective amount of THC is at a concentration of about 0.005% (w/w) to about 0.5% (w/w) of THC in the emulsion composition.

### Claim at position 10

-32. (canceled)

### Claim 33 (depends on 1)

The emulsion composition of claim 1, further comprising an antioxidant.

### Claim at position 12

-41. (canceled)

### Claim 42

An emulsion composition comprising:
a tetrahydrocannabinol (THC), or a derivative thereof;
an oil;
a surfactant; and
water,
wherein the emulsion comprises an oil phase component comprising a plurality of oil droplets dispersed with an aqueous phase component, wherein the osmolarity of the emulsion is substantially similar to human tear fluid osmolarity wherein the THC is (−)-trans-Δ9-tetrahydrocannabinol.

### Claim at position 14

-44. (canceled)

### Claim 45 (depends on 42)

The emulsion composition of claim 42, having an osmolarity of about 300 mOsm/L to about 340 mOsm/L.

### Claim 46

An emulsion composition comprising:
(−)-trans-Δ9-tetrahydrocannabinol;
an oil selected from sesame oil, castor oil, or a combination thereof;
a surfactant selected from the group consisting of Tween®80 (polyoxyethylene (20) sorbitan monooleate); Tween®20 (polyoxyethylene (20) sorbitan monolaurate); Tyloxapol (4-(1,1,3,3-Tetramethylbutyl) phenol polymer with formaldehyde and oxirane); Span 80 (Sorbitane monooleate); Kollipher® HS 15 (polyoxyethylated 12-hydroxystearic acid); polyoxyl 35 castor oil; polyoxyl 40 hydrogenated castor oil; and polyoxyl 40 sterate, or a combination thereof; and
water,
wherein the ratio (w/w) of oil to water in the composition is in the range of about 1:20 to about 1:100, the emulsion comprises an oil phase component comprising a plurality of oil droplets dispersed with an aqueous phase component, wherein at least about 90% of the oil droplets in the emulsion are less than about 200 nm in diameter.

### Claim at position 17

-66. (canceled)

### Claim 67 (depends on 42)

A method of treating or preventing an ophthalmic condition in a subject in need thereof, the method comprising administering to the eye of the subject a therapeutically effective amount of the emulsion composition of claim 42.

### Claim at position 19

-75. (canceled)

### Claim 76 (depends on 67)

The method of claim 67, wherein the ophthalmic condition comprises a blinding eye disease or neuropathic pain.

### Claim 77 (depends on 67)

The method of claim 67, wherein the ophthalmic condition is a neuropathic condition selected from the group consisting of macular degeneration, retinitis pigmentosa, and glaucoma.

### Claim at position 22

-80. (canceled)

### Claim 81 (depends on 1)

A method of treating or preventing an ophthalmic condition in a subject identified in need of such treatment, the method comprising administering to the eye of the subject a therapeutically effective amount of the emulsion composition of claim 1.

### Claim at position 24

-88. (canceled)

### Claim 89 (depends on 81)

The method of claim 81, wherein the ophthalmic condition is selected from the group consisting of glaucoma, age-related macular degeneration (AMD), ophthalmitis, conjunctivitis dry eye disease, posterior uveitis, retinitis, uveoretinitis, proliferative vitreoretinopathy, anterior uveitis, episcleritis, scleritis, ocular neuropathic pain and ocular inflammation caused by a non-infectious condition.

### Claim at position 26

-119. (canceled)

### Claim 120 (depends on 1)

The emulsion composition of claim 1, wherein the pharmaceutically effective amount is an amount effective in treating an ophthalmic condition selected from the group consisting of glaucoma, age-related macular degeneration (AMD), ophthalmitis, conjunctivitis dry eye disease, posterior uveitis, retinitis, uveoretinitis, proliferative vitreoretinopathy, anterior uveitis, episcleritis, scleritis, ocular neuropathic pain and ocular inflammation caused by a non-infectious condition.

### Claim 121 (depends on 120)

The emulsion composition of claim 120, wherein the pharmaceutically effective amount is an amount effective in treating glaucoma.
